Skip to main content
Erschienen in: Osteoporosis International 4/2016

01.04.2016 | Original Article

Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density

verfasst von: C. Ma, B. Shuai, L. Shen, Y. P. Yang, X. J. Xu, C. G. Li

Erschienen in: Osteoporosis International | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

Many epidemiological studies have shown that in some tumors carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and β-catenin appear to be related. However, it remains to be established whether CEACAM1 is related to β-catenin in osteoporosis. Here, we reveal that CEACAM1 might influence the canonical Wnt/β-catenin pathway to modulate bone metabolism in postmenopausal osteoporosis.

Introduction

The aim of this study is to assess the serum level of CEACAM1 in postmenopausal women and its correlation with β-catenin and bone mineral density (BMD).

Methods

The BMD was measured at the lumbar spine (L1–L4) or the femoral neck using dual-energy X-ray absorptiometry (DXA). Serum CEACAM1, β-catenin, receptor activator of nuclear factor kappa-B (RANKL), osteoprotegerin (OPG), β-isomerized C-terminal crosslinking of type I collagen (β-CTX), intact N-terminal propeptide of type I collagen (PINP), estradiol, and insulin were measured in 350 postmenopausal women. Patients were divided according to lumbar spine or femur neck T-scores into osteoporosis (group I), osteopenia (group II), and normal bone mineral density, the latter serving as control.

Results

Serum CEACAM1 levels were significantly lower in group I and II compared to those in control subjects (P < 0.001). Serum CEACAM1 levels correlated positively with β-catenin and BMD, but correlated negatively to the ratio between RANKL and OPG.

Conclusion

This study provides evidence that decreased serum CEACAM1 levels are related to low BMD in postmenopausal women, and that serum CEACAM1 levels correlated positively to β-catenin. It suggests that CEACAM1 might influence the canonical Wnt/β-catenin pathway to modulate bone metabolism.
Literatur
2.
Zurück zum Zitat McClung MR (2003) The menopause and HRT. Prevention and management of osteoporosis. Best Pract Res Clin Endocrinol Metab 17:53–71CrossRefPubMed McClung MR (2003) The menopause and HRT. Prevention and management of osteoporosis. Best Pract Res Clin Endocrinol Metab 17:53–71CrossRefPubMed
3.
Zurück zum Zitat McNamara LM (2010) Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 7:353–372CrossRefPubMed McNamara LM (2010) Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 7:353–372CrossRefPubMed
4.
Zurück zum Zitat Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M (2011) Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-kappaB and MAPK signaling pathways. J Bone Miner Res 26:644–656CrossRefPubMed Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M (2011) Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-kappaB and MAPK signaling pathways. J Bone Miner Res 26:644–656CrossRefPubMed
5.
Zurück zum Zitat Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635–2643CrossRefPubMed Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635–2643CrossRefPubMed
7.
Zurück zum Zitat Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57:272–276CrossRefPubMed Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57:272–276CrossRefPubMed
8.
Zurück zum Zitat Xu XJ, Shen L, Yang YP, Zhu R, Shuai B, Li CG, Wu MX (2013) Serum beta-catenin levels associated with the ratio of RANKL/OPG in patients with postmenopausal osteoporosis. Int J Endocrinol 2013:534352PubMedPubMedCentral Xu XJ, Shen L, Yang YP, Zhu R, Shuai B, Li CG, Wu MX (2013) Serum beta-catenin levels associated with the ratio of RANKL/OPG in patients with postmenopausal osteoporosis. Int J Endocrinol 2013:534352PubMedPubMedCentral
9.
Zurück zum Zitat Jin L, Li Y, Chen CJ, Sherman MA, Le K, Shively JE (2008) Direct interaction of tumor suppressor CEACAM1 with beta catenin: identification of key residues in the long cytoplasmic domain. Exp Biol Med (Maywood) 233:849–859CrossRef Jin L, Li Y, Chen CJ, Sherman MA, Le K, Shively JE (2008) Direct interaction of tumor suppressor CEACAM1 with beta catenin: identification of key residues in the long cytoplasmic domain. Exp Biol Med (Maywood) 233:849–859CrossRef
10.
Zurück zum Zitat Chen D, Iijima H, Nagaishi T, Nakajima A, Russell S, Raychowdhury R, Morales V, Rudd CE, Utku N, Blumberg RS (2004) Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function. J Immunol 172:3535–3543CrossRefPubMed Chen D, Iijima H, Nagaishi T, Nakajima A, Russell S, Raychowdhury R, Morales V, Rudd CE, Utku N, Blumberg RS (2004) Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function. J Immunol 172:3535–3543CrossRefPubMed
11.
Zurück zum Zitat Singer BB, Scheffrahn I, Obrink B (2000) The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. Cancer Res 60:1236–1244PubMed Singer BB, Scheffrahn I, Obrink B (2000) The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. Cancer Res 60:1236–1244PubMed
12.
Zurück zum Zitat Heckt T, Bickert T, Jeschke A, Seitz S, Schulze J, Ito WD, Zimmermann W, Amling M, Schinke T, Horst AK, Keller J (2014) Increased osteoclastogenesis in mice lacking the carcinoembryonic antigen-related cell adhesion molecule 1. PLoS ONE 9, e114360CrossRefPubMedPubMedCentral Heckt T, Bickert T, Jeschke A, Seitz S, Schulze J, Ito WD, Zimmermann W, Amling M, Schinke T, Horst AK, Keller J (2014) Increased osteoclastogenesis in mice lacking the carcinoembryonic antigen-related cell adhesion molecule 1. PLoS ONE 9, e114360CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, Yoneda T (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 96:1953–1960PubMed Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, Yoneda T (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 96:1953–1960PubMed
14.
Zurück zum Zitat Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98:11581–11586CrossRefPubMedPubMedCentral Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98:11581–11586CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Tanaka Y, Maruo A, Fujii K, Nomi M, Nakamura T, Eto S, Minami Y (2000) Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: characteristic involvement of cell cycle regulators. J Bone Miner Res 15:1912–1923CrossRefPubMed Tanaka Y, Maruo A, Fujii K, Nomi M, Nakamura T, Eto S, Minami Y (2000) Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: characteristic involvement of cell cycle regulators. J Bone Miner Res 15:1912–1923CrossRefPubMed
16.
17.
Zurück zum Zitat Eslami B, Zhou S, Van Eekeren I, LeBoff MS, Glowacki J (2011) Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int 88:272–280CrossRefPubMedPubMedCentral Eslami B, Zhou S, Van Eekeren I, LeBoff MS, Glowacki J (2011) Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int 88:272–280CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N, Gregory CA (2010) Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci U S A 107:4147–4152CrossRefPubMedPubMedCentral Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N, Gregory CA (2010) Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci U S A 107:4147–4152CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Johnson ML, Kamel MA (2007) The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 19:376–382CrossRefPubMed Johnson ML, Kamel MA (2007) The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 19:376–382CrossRefPubMed
20.
Zurück zum Zitat Case N, Ma M, Sen B, Xie Z, Gross TS, Rubin J (2008) Beta-catenin levels influence rapid mechanical responses in osteoblasts. J Biol Chem 283:29196–29205CrossRefPubMedPubMedCentral Case N, Ma M, Sen B, Xie Z, Gross TS, Rubin J (2008) Beta-catenin levels influence rapid mechanical responses in osteoblasts. J Biol Chem 283:29196–29205CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Zhang R, Oyajobi BO, Harris SE, Chen D, Tsao C, Deng HW, Zhao M (2013) Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 52:145–156CrossRefPubMed Zhang R, Oyajobi BO, Harris SE, Chen D, Tsao C, Deng HW, Zhao M (2013) Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 52:145–156CrossRefPubMed
22.
Zurück zum Zitat Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL (2006) Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 21:910–920CrossRefPubMed Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL (2006) Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 21:910–920CrossRefPubMed
23.
Zurück zum Zitat Borchert KM, Galvin RJ, Frolik CA, Hale LV, Halladay DL, Gonyier RJ, Trask OJ, Nickischer DR, Houck KA (2005) High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay Drug Dev Technol 3:133–141CrossRefPubMed Borchert KM, Galvin RJ, Frolik CA, Hale LV, Halladay DL, Gonyier RJ, Trask OJ, Nickischer DR, Houck KA (2005) High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay Drug Dev Technol 3:133–141CrossRefPubMed
24.
Zurück zum Zitat Price MA (2006) CKI, there's more than one: casein kinase I family members in Wnt and hedgehog signaling. Genes Dev 20:399–410CrossRefPubMed Price MA (2006) CKI, there's more than one: casein kinase I family members in Wnt and hedgehog signaling. Genes Dev 20:399–410CrossRefPubMed
25.
Zurück zum Zitat Patel S, Doble B, Woodgett JR (2004) Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword? Biochem Soc Trans 32:803–808CrossRefPubMedPubMedCentral Patel S, Doble B, Woodgett JR (2004) Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword? Biochem Soc Trans 32:803–808CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Huang SKMHM (2010) Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 46:1138–1145CrossRefPubMedPubMedCentral Huang SKMHM (2010) Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 46:1138–1145CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Poy MN, Ruch RJ, Fernstrom MA, Okabayashi Y, Najjar SM (2002) Shc and CEACAM1 interact to regulate the mitogenic action of insulin. J Biol Chem 277:1076–1084CrossRefPubMed Poy MN, Ruch RJ, Fernstrom MA, Okabayashi Y, Najjar SM (2002) Shc and CEACAM1 interact to regulate the mitogenic action of insulin. J Biol Chem 277:1076–1084CrossRefPubMed
28.
Zurück zum Zitat Kuespert K, Pils S, Hauck CR (2006) CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 18:565–571CrossRefPubMed Kuespert K, Pils S, Hauck CR (2006) CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 18:565–571CrossRefPubMed
30.
Zurück zum Zitat Muller B (2002) Cytokine imbalance in non-immunological chronic disease. Cytokine 18:334–339CrossRefPubMed Muller B (2002) Cytokine imbalance in non-immunological chronic disease. Cytokine 18:334–339CrossRefPubMed
31.
Zurück zum Zitat Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176CrossRefPubMed Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176CrossRefPubMed
32.
Zurück zum Zitat Mulcahy LE, Taylor D, Lee TC, Duffy GP (2011) RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. Bone 48:182–188CrossRefPubMed Mulcahy LE, Taylor D, Lee TC, Duffy GP (2011) RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. Bone 48:182–188CrossRefPubMed
33.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed
34.
Zurück zum Zitat Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251–264CrossRefPubMed Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251–264CrossRefPubMed
35.
Zurück zum Zitat Kung AW, Fan T, Xu L, Xia WB, Park IH, Kim HS, Chan SP, Lee JK, Koh L, Soong YK, Soontrapa S, Songpatanasilp T, Turajane T, Yates M, Sen S (2013) Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 13:7CrossRefPubMedPubMedCentral Kung AW, Fan T, Xu L, Xia WB, Park IH, Kim HS, Chan SP, Lee JK, Koh L, Soong YK, Soontrapa S, Songpatanasilp T, Turajane T, Yates M, Sen S (2013) Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 13:7CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Riggs BL, Khosla S, Melton LR (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302CrossRefPubMed Riggs BL, Khosla S, Melton LR (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302CrossRefPubMed
37.
Zurück zum Zitat Wang JL, Sun SZ, Qu X, Liu WJ, Wang YY, Lv CX, Sun JZ, Ma R (2011) Clinicopathological significance of CEACAM1 gene expression in breast cancer. Chin J Physiol 54:332–338CrossRefPubMed Wang JL, Sun SZ, Qu X, Liu WJ, Wang YY, Lv CX, Sun JZ, Ma R (2011) Clinicopathological significance of CEACAM1 gene expression in breast cancer. Chin J Physiol 54:332–338CrossRefPubMed
38.
Zurück zum Zitat Hyder SM, Nawaz Z, Chiappetta C, Stancel GM (2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60:3183–3190PubMed Hyder SM, Nawaz Z, Chiappetta C, Stancel GM (2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60:3183–3190PubMed
39.
Zurück zum Zitat Ergun S, Kilik N, Ziegeler G, Hansen A, Nollau P, Gotze J, Wurmbach JH, Horst A, Weil J, Fernando M, Wagener C (2000) CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 5:311–320CrossRefPubMed Ergun S, Kilik N, Ziegeler G, Hansen A, Nollau P, Gotze J, Wurmbach JH, Horst A, Weil J, Fernando M, Wagener C (2000) CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 5:311–320CrossRefPubMed
Metadaten
Titel
Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density
verfasst von
C. Ma
B. Shuai
L. Shen
Y. P. Yang
X. J. Xu
C. G. Li
Publikationsdatum
01.04.2016
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 4/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3408-3

Weitere Artikel der Ausgabe 4/2016

Osteoporosis International 4/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.